PETALUMA, Calif., April 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty
pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and
advanced tissue care, today announced it has received four new regulatory approvals from the United Arab Emirates Ministry of
Health & Prevention. The family of approved products include an acne treatment as well as anti-fungal therapies, among others.
“These new MicroSafe products will further advance the common methods for treating skin infections in a safer and more
efficacious manner,” said Safa Qadumi, managing director for the MicroSafe Group, which is the exclusive distributor of Sonoma
Pharmaceutical products throughout the Middle East. “We anticipate launching all four products immediately into pharmacies
throughout the United Arab Emirates.” The four approvals, all under the provisions of the UAE’s General Sale List (GSL), encompass
hypochlorous acid-based products for treatment of acne as well as anti-fungal indications.
“Sonoma remains very proud of its partnership with the MicroSafe group and their expanding indications using Sonoma’s
proprietary Microcyn Technology. We are especially pleased with these UAE approvals that should lead to adoption by other Middle
Eastern countries,” said Bruce Thornton, EVP of international operations and sales for Sonoma Pharmaceuticals.
Contact MicroSafe Group at safa.microsafe@gmail.com for distribution inquires relative to the Gulf and Middle Eastern
countries.
About MicroSafe Group
The MicroSafe Group distributes products manufactured by Sonoma Pharmaceuticals based upon the Microcyn® Technology platform. The
MicroSafe Group has operations in several countries with its head office in Dubai, United Arab Emirates. With several regional
offices in the Middle East as well as Australia, they provide innovative solutions to a wide range of industries and healthcare
providers. The MicroSafe group promotes only those products it believes will truly revolutionize healthcare – products that will
enrich the lives of patients and healthcare professionals all over the world.
About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of
dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain,
scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands.
More information can be found at www.sonomapharma.com
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries. These
forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others.
Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks that regulatory clinical and guideline developments
may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient settings, protection offered by the
company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the
available market for the company’s products will not be as large as expected, the company’s products will not
be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical
studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with
the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as
required by law.
Sonoma® Pharmaceuticals is a registered trademark of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the
property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden@sonomapharma.com
